AKT1 and Miyoshi myopathy: The first generation small molecule Met inhibitor SU11274 has been successfully used to impair proliferation, wound healing and motility of H28 MM cells, by inhibiting Met kinase activity and downstream phosphorylation of Erk1/2 and Akt [44].